Infinity Pharmaceuticals, Inc. (INFI) announced positive results from two phase I studies on IPI-145, being developed for the treatment of patients suffering from relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Investors reacted positively to the news and shares were up 2.6% on Dec 9.
Infinity Pharma announced results from a phase I study on IPI-145 in patients suffering from iNHL, a potentially fatal hematologic malignancy (blood cancer). Results from the study revealed an overall response rate of 73% including three complete responses in patients receiving IPI-145. Additionally, data showed that 53% patients were progression free for more than a year.
The company presented these data at the 55th annual meeting of the American Society of Hematology (ASH). Results from the study support Infinity Pharma’s ongoing phase II DYNAMO study of IPI-145 in patients suffering from refractory iNHL.
Infinity Pharma is currently enrolling patients for its DYNAMO study (n=120). The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.’s (RHHBY/BIIB) Rituxan (rituximab) and chemotherapy and who have progressed within six months of receiving their last therapy. The primary objective of the study is to evaluate the response rate according to the International Working Group (IWG) criteria.
Infinity Pharma also announced results from a phase I study on IPI-145 in patients suffering from CLL, another potentially fatal hematologic malignancy (blood cancer). Results from this study revealed that a nodal response rate of 89% and an overall response rate of 48%, as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria1, were observed in patients treated with IPI-145.
IPI-145 was also generally well tolerated in the study. Results from the study also support Infinity Pharma’s phase III DUO study (n=300) on IPI-145 in patients suffering from relapsed/refractory CLL. The DUO study will evaluate the safety and efficacy of IPI-145 in CLL patients. The main objective of the study is to evaluate progression-free survival in these patients.
We are encouraged by Infinity Pharma’s progress with its pipeline. We expect investor focus to remain on the company’s pipeline going forward.
Infinity Pharma carries a Zacks Rank #2 (Buy). Some other stocks worth considering include Zacks Ranked #1 (Strong Buy) Actelion Ltd. (ALIOF).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment